drugset / Trial / NCT00471094

Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis

NCT00471094

Phase 2 Completed 831 enrolled Takeda
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to assess the efficacy and safety of 8 weeks of daily treatment with Ilaprazole (5, 20 and 40 mg), once daily (QD), compared to lansoprazole 30 mg in healing subjects with endoscopically proven erosive esophagitis.

Timeline

Start
2007-05
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ilaprazole Small molecule 5 mg Oral
Subject Ilaprazole Small molecule 20 mg Oral
Subject Ilaprazole Small molecule 40 mg Oral
Comparator Lansoprazole Other / unclassified 30 mg Oral

Indications